Tadalafil

Generic Name: Tadalafil

Brand Names: Adcirca, Alyq, Cialis, Entadfi, Tadliq, Talmanco (previously Tadalafil Generics), Tadalafil Mylan, Tadalafil Lilly, Adcirca (previously Tadalafil Lilly)

Drug Type: Small Molecule

Chemical Formula: C_₂₂H_₁₉N_₃O_₄

CAS Number: 171596-29-5

Unique Ingredient Identifier: 742SXX0ICT

Background: Tadalafil is a selective phosphodiesterase-5 inhibitor that is used in the treatment of erectile dysfunction (ED), pulmonary arterial hypertension (PAH), and benign prostatic hypertrophy. It was first approved in 2003 by the FDA for use in ED and later in 2009 for PAH. In contrast to other PDE5 inhibitors like sildenafil, tadalafil has greater selectivity for PDE5 and a longer half-life which has made it a more suitable option for chronic once-daily dosing in the treatment of PAH.

Indication: Tadalafil is indicated for the treatment of erectile dysfunction (ED) and either alone or in combination with finasteride for the treatment of benign prostatic hypertrophy (BPH). It is also indicated for the treatment of pulmonary arterial hypertension (PAH) both alone and in combination with macitentan or other endothelin-1 antagonists.

Associated Conditions: Benign Prostatic Hyperplasia (BPH), Erectile Dysfunction, Pulmonary Arterial Hypertension (PAH)

Associated Therapies: -

Clinical Trials

Determine If the Stress That Comes With Not Developing an Erection Affects Tadalafil Effects

Phase 4

Completed

Conditions: Impotence

Interventions: Drug: tadalafil

First Posted Date: 2007-10-22

Last Posted Date: 2007-10-22

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 659

Registration Number: NCT00547599

Locations: 🇸🇪
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Uppsala, Sweden

Study the Safety and Effectiveness of Tadalafil in Men With Diabetes Who Have Problems Getting and Keeping an Erection

Phase 3

Completed

Conditions: Impotence

Interventions: Drug: tadalafil
Drug: placebo

First Posted Date: 2007-10-22

Last Posted Date: 2007-10-22

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 298

Registration Number: NCT00547183

Locations: 🇩🇪
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Genthin, Germany

To Determine How Different Doses of Tadalafil Work on Getting and Keeping an Erection 26 or 36 Hours After Taking

Phase 3

Completed

Conditions: Impotence

Interventions: Drug: placebo
Drug: tadalafil

First Posted Date: 2007-10-22

Last Posted Date: 2007-10-22

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 485

Registration Number: NCT00547508

Locations: 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Knoxville, Tennessee, United States

Studying the Preference of Tadalafil to Sildenafil in Men With Problems Getting an Erection Across Nations

Phase 3

Completed

Conditions: Impotence

Interventions: Drug: sildenafil
Drug: tadalafil

First Posted Date: 2007-10-22

Last Posted Date: 2007-10-22

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 2760

Registration Number: NCT00547287

Locations: 🇧🇷
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sao Paulo, Brazil

Study to Determine a Preference Between Sildenafil or Tadalafil Treatment for Problems Getting an Erection

Phase 4

Completed

Conditions: Impotence

Interventions: Drug: tadalafil
Drug: sildenafil

First Posted Date: 2007-10-22

Last Posted Date: 2007-10-22

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 160

Registration Number: NCT00547352

Locations: 🇰🇷
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon- Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Seoul, Korea, Republic of

Study the Safety and Effectiveness of Tadalafil in Men With Problems Getting or Maintaining an Erection When Taken Prior to Desiring an Erection

Phase 3

Completed

Conditions: Impotence

Interventions: Drug: placebo
Drug: tadalafil

First Posted Date: 2007-10-22

Last Posted Date: 2007-10-22

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 343

Registration Number: NCT00547495

Locations: 🇯🇵
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon- Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sapporo, Hokkaido, Japan

Pilot Study Investigating Safety and Efficacy of Tadalafil as Treatment for Benign Prostatic Hyperplasia (BPH) in Asian Men

Phase 2

Completed

Conditions: Benign Prostatic Hyperplasia

Interventions: Drug: Placebo
Drug: Tadalafil
Drug: Tamsulosin

First Posted Date: 2007-10-05

Last Posted Date: 2010-11-25

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 151

Registration Number: NCT00540124

Locations: 🇰🇷
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Seoul, Korea, Republic of